Generating biologically relevant cell models is often the slowest and most critical step in the drug discovery process. For targeted protein degradation (TPD) and other small-molecule programs, real-time quantification of endogenous protein levels can provide decisive insights; however, conventional antibody assays and overexpression systems can add weeks to timelines.
Join Promega and EditCo to discover a streamlined path from CRISPR edit to actionable data. You’ll see how a single 11-amino-acid HiBiT tag, precisely inserted by EditCo and verified by deep NGS, converts your protein of interest into a bright Nano-Glo® biosensor with >6-log linear dynamic range. Then learn how Promega’s ready-made assays and high- throughput screening services translate that signal into degrader potency curves and kinetic profiles—often within days of receiving your cells.
In this session, you’ll learn:
- HiBiT fundamentals: why a tag this small delivers such a big, quantitative signal.
- Editing at speed: how EditCo ships HiBiT knock-in pools or clones—NGS-verified and assay-ready—in as little as 10 weeks.
- Assay to insight: leveraging Promega’s platforms to profile degrader efficacy, kinetics, and selectivity.
- Beyond TPD: extending the same models to pathway modulation, target validation, and ortholog studies across your discovery pipeline.
Cut months off discovery timelines and illuminate your next breakthrough—faster than ever. (Co-sponsored by Promega Corporation and EditCo Bio)
Fill out the form below to watch the webinar!
